Placebo for eczema

A treatment and a condition, followed through the public trial records. Not medical advice. How a status is set

Phase 3 trial. Large late-stage trial in people. As of 19 Nov 2026, from 2 registered trials.

Why this status

  1. 15 Feb 2017: Trial registered, NCT03054428
  2. 21 Mar 2017: Trial started, NCT03054428

The trials

NCT03054428: Efficacy and Safety of Dupilumab in Participants ≥12 to <18 Years of Age, With Moderate-to-severe Atopic Dermatitis

State
Completed
Phase
Phase 3
People
251 taking part
Started
21 Mar 2017
Primary completion
4 Apr 2018
Arms
Placebo
Results
Posted on the registry
Papers
doi:10.1001/jamadermatol.2019.3336, doi:10.1001/jamadermatol.2022.6192, doi:10.1002/cpt.2366, doi:10.1007/s13555-019-00333-2, doi:10.1007/s13555-021-00568-y, doi:10.1007/s40257-019-00478-y, doi:10.1007/s40257-020-00577-1, doi:10.1007/s40257-020-00583-3, doi:10.1007/s40257-022-00683-2, doi:10.1007/s40257-025-00952-w, doi:10.1016/j.jaad.2020.02.060, doi:10.1111/bjd.18476, doi:10.3389/fimmu.2024.1466372
  1. 15 Feb 2017: Trial registered
  2. 21 Mar 2017: Trial started
  3. 5 Jun 2018: Trial completed
  4. 23 Jul 2019: Trial results posted

How the status changed

  1. 19 Nov 2026: First set: Phase 3 trial

Registries searched: ClinicalTrials.gov, through 17 Nov 2026.